homology

NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.

Tetramethylcurcumin is a novel curcumin analog, is an effective inhibitors of STAT3 phosphorylation, DNA binding activity, and transactivation in vitro.it also inhibits colony formation in soft agar, cell invasion, and exhibit synergy with the anti-cancer drug doxorubicin against breast cancer cells.

SMIFH2 is formin homology 2 (FH2) domains inhibitor.

NSC45586 is a protein phosphatase PHLPP inhibitor, which is selective for PHLPP1 and PHLPP2.

2-Bromo-4'-hydroxyacetophenone(PTP Inhibitor I) is a cell-permeable, protein tyrosine phosphatase (PTP) inhibitor that covalently blocks the catalytic domain of the Src homology region 2 domain-containing phosphatase (SHP-1(ΔSH2)) with a Ki value of 43 μM and PTP1B with a Ki value of 42 μM [1]. SHP-1 and PTP1B both have known roles in regulating insulin signaling as well as myeloid and lymphoid cell differentiation, making inhibitors of these phosphatases of interest in diabetes, cancer, allergy, and inflammation research [2].

PTP inhibitor 1 is an inhibitor of cell-permeable protein tyrosine phosphatase (PTP) that covalently binds the catalytic domain of the Src homology region 2 domain-containing phosphatase (SHP-1(ΔSH2)),with Ki of128 μM.

CS1 peptide is present within type III homology connecting segment (IIICS) as well as C-274 (cell-binding domain). Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastas

FPA-124 is a cell-permeable copper complex that acts as a selective Akt (protein kinase B) inhibitor interacting with the homology (PH) and kinase structural domains of Akt to induce apoptosis. It has the advantage of being highly potent and exhibits dose-dependent growth inhibition in a variety of cancer cell lines.

NSC117079 is a novel PHLPP1/2 (Pleckstrin homology domain and leucine rich repeat protein phosphatase) inhibitor that activates neuronal AKT and ameliorates staurosporine-induced cell death in neurons.

PHT-7.3 is a selective connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain inhibitor

TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 µM),with potential antineoplastic activity.

Bragsin2 (6-methoxy-5-nitro-2-(trifluoromethyl)chromen-4-one) is a hydration-resistant cell penetrant, selective and non-competitive inhibitor of Afr guanine nucleotide exchange factor BRAG2 that inhibits Arf GTPase activation, with an IC50 of 3 μM. Bragsin2 binds at the interface between the pleckstrin homology domain of BRAG2 and the lipid bilayer, leading BRAG2 unable to activate lipidated Arf GTPase.

SCR7 pyrazine (SCR7) enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).

YL-5092 is a YTHDC1 inhibitor (IC50=7.4 nM, KD=29.6 nM) that suppresses cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and can be used in studies of acute myeloid leukemia (AML).

SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.

AKT-IN-26 (Compound 453) is an AKT inhibitor that binds to the Pleckstrin Homology (PH) domain of AKT. It is useful for research related to cell proliferation and cancer involving the AKT pathway.

YTHDF2-IN-1 (Compound CK-75) is an inhibitor of YT521-B homology domain family 2 (YTHDF2) with a dissociation constant (Kd) of 26.2 μM, and it effectively blocks the interaction between YTHDF2 and m6A RNA. It suppresses colony formation in JAR cells and exhibits antiproliferative activity in various cancer cell lines, with an IC50 in the micromolar range. Additionally, YTHDF2-IN-1 induces apoptosis in K562 cells and causes cell cycle arrest at the G0/G1 phase.

SHP2-IN-28 (Compound 7188-0011) is an inhibitor of Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) with an IC50 of 54.31 μM. It exerts its inhibitory effect by binding to the allosteric site of SHP2, displaying high selectivity.

SHP2-IN-42 is an inhibitor of the phosphatase containing the Src homology 2 domain (SHP2), with an IC50 of 15 nM. It inhibits cell proliferation, induces apoptosis, and causes G1 phase cell cycle arrest. SHP2-IN-42 is applicable in cancer research, including studies on acute myeloid leukemia (AML).

trans-UHMCP1 is the trans isomer of UHMCP1. UHMCP1 serves as a chemical probe for the U2AF homology motif (UHM), with a dissociation constant (Kd) of 79 μM. It inhibits the interaction between SF3b155 and U2AF65, thereby affecting RNA splicing and cellular viability. Additionally, UHMCP1 possesses potential anticancer properties.

BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) that specifically binds to the N-terminal of BACH1 with a dissociation constant (Kd) of 9.0 μM. It interferes with the interaction between BACH1 and HDAC1, increases H3K27 acetylation at BACH1 target genes, and promotes the expression of angiogenic genes, indicating its potential therapeutic use for myocardial infarction and ischemic vascular diseases.

Cy5-MicroRNA Mimic Negative Control is a Cy5-labeled MicroRNA Mimic Negative Control. This compound is a 21-nucleotide miRNA mimic used as a negative control. The sequence of the MicroRNA Mimic Negative Control is designed based on the cel-mir-239b sequence, which is widely utilized as a negative control. It exhibits minimal sequence homology with human, mouse, and rat miRNA.

CHS-111 is a benzyl indazole compound that inhibits superoxide anion (O(2)(-)) generation and reduces fMLP-stimulated PLD activity (IC(50) 3.9±1.2μM). It inhibits the interaction of PLD1 with ADP-ribosylation factor (Arf) 6 and Ras homology (Rho) A, and reduces the membrane recruitment of RhoA in fMLP-stimulated cells.

1-O-Octadecyl-2-O-methyl-sn-glycerol is a metabolite of a phosphotidylinositol ether lipid analog (PIA). PIAs are known to target the pleckstrin homology domain of the serine/threonine kinase Akt and to induce apoptosis in cancer cell lines with high levels of endogenous Akt activity.